Finance

Beta
Lists
ANEB:OTCMKTS
Anebulo Pharmaceuticals Inc
$0.47
+21.70%
(+0.085) 1D
Jun 12, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ANEB...
Open
$0.44
High
$0.47
Low
$0.44
Mkt. cap
19.37M
Avg. vol.
4.20K
Volume
493.00
52-wk high
$3.42
52-wk low
$0.30
EPS
-$0.19
Beta
-1.87
Shares outstanding
40.78M
No. of employees
3
Open
$0.44
High
$0.47
Low
$0.44
Mkt. cap
19.37M
Avg. vol.
4.20K
Volume
493.00
52-wk high
$3.42
52-wk low
$0.30
EPS
-$0.19
Beta
-1.87
Shares outstanding
40.78M
No. of employees
3
News stories
From sources across the web
About Anebulo Pharmaceuticals Inc
CEO-
Employees3
Founded2020
HeadquartersLakeway, Texas, United States
SectorPharmaceutical industry
Websiteanebulo.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
638.32K
1.13M
809.99K
1.16M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.25M
1.20M
1.45M
1.46M
Operating expense
1.89M
2.33M
2.26M
2.62M
Total operating expenses
1.89M
2.33M
2.26M
2.62M
Operating income
-1.89M
-2.33M
-2.26M
-2.62M
Other non operating income
359.08K
80.91K
9.73K
552.54K
EBT including unusual items
-1.68M
-2.14M
-2.16M
-2.00M
EBT excluding unusual items
-1.68M
-2.14M
-2.16M
-2.00M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-1.68M
-2.14M
-2.16M
-2.00M
Net profit margin
-
-
-
-
Earnings per share
-0.04
-0.05
-
-
Interest and investment income
102.26K
122.58K
109.62K
85.41K
Interest expense
-245.18K
-17.44K
-17.44K
-17.44K
Net interest expenses
-142.92K
105.14K
92.18K
67.97K
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer